FYR Diagnostics
FYR Diagnostics is developing a powerful portfolio of biomarker detection technologies with a focus on nucleic acid amplification. Our mission is to commercialize and implement these novel technologies to enable the accelerated prediction, diagnosis, and management of human and agricultural diseases. We are currently using novel detection technologies to develop next generation biomarkers for applications in human health such as cancers, neurodegenerative conditions, and pathogenic diseases. We are also applying these technologies to develop biomarkers for crop and livestock diseases in agriculture.
Company details
Find locations served, office locations
- Business Type:
- Service provider
- Industry Type:
- Clinical Services
- Market Focus:
- Nationally (across the country)
About Us
Biomarkers, which are quantifiable indicators of disease states, are critical for informing how to manage disease. There is a current need for the development of the next generation of biomarkers, which are non-invasive, rapid, and accurate. In addition to having diagnostic utility, there is also a need for predictive and prognostic biomarkers to predict disease states before they develop and to monitor treatment and outcomes during disease transitions.
FYR Diagnostics is an accredited CLIA (Clinical Laboratory Improvement Amendments) licensed laboratory specializing in high-complexity diagnostic testing for COVID-19. Our current testing methodology utilizes RT-PCR technology approved for Emergency Use Authorization by the FDA coupled with an advanced automation platform.
Pandemic Response Taskforce
FYR’s Missoula-based team is comprised of numerous researchers and operations specialists who are actively monitoring SARS-CoV-2 variants and their impact on our region. FYR maintains close contact with state and federal officials and actively collaborates with the Montana Department of Public Health and Human Services.
FYR’s task force is actively monitoring the various research developments related to SARS-CoV-2, including variants of concern and their potential impact on transmissibility, severity of disease, effectiveness of vaccines, and effectiveness of testing (both PCR and rapid antigen tests, along with effectiveness of specific viral gene detection, sequencing methodologies, etc.).
Each day, FYR’s Pandemic Response Taskforce monitors the following:
- WHO, CDC, FDA, scientific literature, and other announcements related to variants of concern impact on transmissibility, severity of disease, effectiveness of vaccines, surveillance with sequencing, and effectiveness of testing (both PCR and rapid antigen testing methodologies)
- Viral gene detection effectiveness with PCR based on novel mutations in emerging variants
- Local, State, Federal, and Worldwide variant spread and variant-specific risk factors